ICML 2017 | Insights from the RAY trial: treating relapsed mantle cell lymphoma patients
Simon Rule, MD from Plymouth University, Plymouth, UK discusses the duration of response observed in patients taking part in the RAY (MCL3001) trial (NCT01646021). Following the latest trial update presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Prof. Rule explains that patients receiving ibrutinib treatment have a limited duration of response and following treatment failure and that there are a number of secondary treatment options for patients. From the RAY trial results it has been possible to examine how patients respond to such secondary treatments. This has provided great insight into how and when is best treat patients who have relapsed.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.
